Association of Osteoprotegerin With Aortic Stiffness in Patients With Symptomatic Peripheral Artery Disease and in Healthy Subjects

Zagura, Maksim; Serg, Martin; Kampus, Priit; Zilmer, Mihkel; Zilmer, Kersti; Eha, Jaan; Unt, Eve; Lieberg, J.; Kals, Jaak

doi:10.1038/ajh.2010.38

Cited by 38 publications

(30 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings are consistent with other human studies that have demonstrated associations between higher serum OPG levels and various adverse cardiovascular outcomes (14,15,17,20,31,32). These findings in humans are in contrast to studies in OPG-deficient mice who exhibit diffuse medial calcification of the aorta and renal arteries because of low OPG levels (6).…”

Section: Discussioncontrasting

confidence: 54%

Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease

Scialla

Leonard

Townsend

et al. 2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives Osteoprotegerin (OPG), a cytokine that regulates bone resorption, has been implicated in the process of vascular calcification and stiffness.Design, setting, participants, & measurements Serum OPG was measured in 351 participants with chronic kidney disease (CKD) from one site of the Chronic Renal Insufficiency Cohort Study. Cortical bone mineral content (BMC) was measured by quantitative computed tomography in the tibia. Multivariable linear regression was used to test the association between serum OPG and traditional cardiovascular risk factors, measures of abnormal bone and mineral metabolism, and pulse wave velocity. ResultsHigher serum OPG levels were associated with older age, female gender, greater systolic BP, lower estimated GFR, and lower serum albumin. OPG was not associated with measures of abnormal bone or mineral metabolism including serum phosphorus, albumin-corrected serum calcium, intact parathyroid hormone, bone-specific alkaline phosphatase, or cortical BMC. Among 226 participants with concurrent aortic pulse wave velocity measurements, increasing tertiles of serum OPG were associated with higher aortic pulse wave velocity after adjustment for demographics, traditional vascular risk factors, and nontraditional risk factors such as estimated GFR, albuminuria, serum phosphate, corrected serum calcium, presence of secondary hyperparathyroidism, serum albumin, and C-reactive protein or after additional adjustment for cortical BMC in a subset (n ϭ 161).Conclusions These data support a strong relationship between serum OPG and arterial stiffness independent of many potential confounders including traditional cardiovascular risk factors, abnormal bone and mineral metabolism, and inflammation.

show abstract

Section: Discussioncontrasting

confidence: 54%

Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease

Scialla

Leonard

Townsend

et al. 2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Serum OPG levels and PWV were found to be significantly higher in diabetic patients than in the normoglycaemic group, and there is a significant association between serum OPG with inflammation and arterial stiffness [14]. Although other authors manifest that serum levels of OPG were not correlated to PWV [102], Zagura et al [103] indicated that the independent association between OPG and PWV observed in patients with peripheral artery disease (PAD) and in controls suggests that the calcification inhibitor OPG may influence aortic stiffening in atherosclerosis and in clinically healthy subjects. Taking together all these findings, we therefore conclude that increased OPG plasma levels observed during diabetes may favour the development of endothelial dysfunction in these patients.…”

Section: Opg and Endothelial Dysfunction In Diabetesmentioning

confidence: 98%

Osteoprotegerin and Diabetes-Associated Pathologies

Blázquez‐Medela

Jm²,

Martı́nez-Salgado³

2011

CMM

View full text Add to dashboard Cite

Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.

show abstract

“…The OPN is an important inhibitor of vascular calcification. 21 As PAD is associated with vascular calcification, 22,23 it might be that increased serum OPN represents a compensatory mechanism aiming to inhibit progression of vascular calcification. However, further experimental studies are needed to determine the exact role of OPN in arterial stiffening.…”

Section: Discussionmentioning

confidence: 99%

Structural and biochemical characteristics of arterial stiffness in patients with atherosclerosis and in healthy subjects

et al. 2012

View full text Add to dashboard Cite

Arterial stiffness is an independent predictor of vascular morbidity and mortality in patients with atherosclerosis. Angiographic score (ASc) reflects severity of atherosclerosis in patients with peripheral arterial disease (PAD). Osteopontin (OPN) and oxidized low-density lipoprotein (oxLDL) are involved in the pathogenesis of atherosclerosis. The aim of the present study was to evaluate the association between arterial stiffness, ASc, serum OPN and oxLDL in patients with symptomatic PAD, and in clinically healthy subjects. We studied 79 men with symptomatic PAD (mean age 64 ± 7 years) and 84 healthy men (mean age 63 ± 8 years). Calculation of the ASc was based on severity and location of atherosclerotic lesions in the arteries of the lower extremities. Aortic pulse wave velocity (aPWV) was evaluated by applanation tonometry using the Sphygmocor device. Serum OPN and oxLDL levels were determined by enzyme-linked immunosorbent assay. The aPWV (10 ± 2.4 VS. 8.4 ± 1.7 (m s À1 ); Po0.001), ) VS. 54.8 (47.7-67.9) (ng ml À1 ); Po0.001) and oxLDL (67 (52.5-93.5) VS. 47.5 (37-65.5); Po0.001) were different for the patients and for the controls. In multiple regression models, aPWV was independently determined by ASc, log-OPN, log-oxLDL and estimated glomerular filtration rate in the patients (R 2 ¼ 0.44; Po0.001) and by log-OPN, log-oxLDL, age and heart rate in the controls (R 2 ¼ 0.38; Po0.001). The independent relationship of a PWV with serum levels of OPN and oxLDL in the patients with PAD and in the controls indicates that OPN and oxLDL might influence arterial stiffening in patients with atherosclerosis and in clinically healthy subjects.

show abstract

Association of Osteoprotegerin With Aortic Stiffness in Patients With Symptomatic Peripheral Artery Disease and in Healthy Subjects

Abstract: The independent association between OPG and aPWV in patients with PAD and in controls suggests that the calcification inhibitor OPG may influence aortic stiffening in atherosclerosis and in clinically healthy subjects.

Cited by 38 publications

References 23 publications

Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease

Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease

Osteoprotegerin and Diabetes-Associated Pathologies

Structural and biochemical characteristics of arterial stiffness in patients with atherosclerosis and in healthy subjects

Contact Info

Product

Resources

About